CYP2C8 and malaria: Here it is reported a non-negligible frequency of 26.1% of CYP2C8*2-carriers in an area of low malaria transmission, where CQ was still used for therapy and prophylaxis although it has been replaced by AS plus AQ combination therapy as the first-line treatment for uncomplicated cases since 2005 [30].